Dynamic contrast-enhanced MRI monitoring proofs inhibition of tumor growth and angiogenesis in experimental prostate carcinomas by sorafenib

E. Bettina Schwarz, Clemens C. Cyran, Philipp Paprottka, Steven Sourbron, Jobst Von Einem, Rabea Hinkel, Bernd J. Wintersberger, Konstantin Nikolau, Maximilian F. Reiser & Christiane J. Bruns
Introduction: The oral multikinase inhibitor sorafenib has been approved for the treatment of advanced HCC and metastatic RCC. Up to now, there is no data on its potential anti-angiogenic and anti-proliferative effects on other tumor entities. Our aim was to investigate the anti-angiogenic effects of[for full text, please go to the a.m. URL]